An overview of statistical methods for handling nonadherence to intervention protocol in randomized control trials: a methodological review by Mostazir, Mohammod et al.
 
 
 
 
 
 
 
Mostazir, M., Taylor, R. S. , Henley, W. and Watkins, E. (2019) An 
overview of statistical methods for handling nonadherence to intervention 
protocol in randomized control trials: a methodological review. Journal of 
Clinical Epidemiology, 108, pp. 121-131.  
(doi:10.1016/j.jclinepi.2018.12.002) 
 
There may be differences between this version and the published version. 
You are advised to consult the publisher’s version if you wish to cite from 
it.  
 
 
http://eprints.gla.ac.uk/196774/  
 
 
 
 
 
 
   Deposited on 09 January 2019 
 
 
 
 
 
 
 
 
 
 
 
 
Enlighten – Research publications by members of the University of       
           Glasgow 
http://eprints.gla.ac.uk  
 
Accepted Manuscript
An overview of statistical methods for handling non-adherence to intervention protocol
in randomised control trials (RCTs): A methodological review
Mohammod Mostazir, Rod S. Taylor, William Henley, Ed Watkins
PII: S0895-4356(18)30494-3
DOI: https://doi.org/10.1016/j.jclinepi.2018.12.002
Reference: JCE 9795
To appear in: Journal of Clinical Epidemiology
Received Date: 30 May 2018
Revised Date: 29 October 2018
Accepted Date: 4 December 2018
Please cite this article as: Mostazir M, Taylor RS, Henley W, Watkins E, An overview of statistical
methods for handling non-adherence to intervention protocol in randomised control trials (RCTs):
A methodological review, Journal of Clinical Epidemiology (2019), doi: https://doi.org/10.1016/
j.jclinepi.2018.12.002.
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to
our customers we are providing this early version of the manuscript. The manuscript will undergo
copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please
note that during the production process errors may be discovered which could affect the content, and all
legal disclaimers that apply to the journal pertain.
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
1 | P a g e  
 
 
 
 
 
An overview of statistical methods for handling non-adherence to 
intervention protocol in randomised control trials (RCTs): A 
methodological review 
 
Mohammod Mostazira, Rod S Taylorb, William Henleyb, Ed Watkinsc 
 
aCollege of life and Environmental Sciences (CLES), University of Exeter, EX4 4QG, United 
Kingdom, bInstitute of Health Research, University of Exeter Medical School, University of 
Exeter, EX1 2LU, United Kingdom, cMood Disorders Research, School of Psychology, 
College of Life & Environmental Sciences, University of Exeter, EX4 4QG, United Kingdom 
 
 
 
 
 
Declarations of interest: None  
 
 
 
 
 
 
 
Correspondence to:  
Mohammod Mostazir 
College of life and Environmental Sciences (CLES),  
University of Exeter  
EX4 4QG, Exeter UK 
T: +44 1392 726629 
M: +44 7432516771 
Email: m.mostazir@exeter.ac.uk 
 
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
2 | P a g e  
 
 
 
 
 
Abstract 
Objective 
To undertake a methodological review of statistical methods used in randomised 
controlled trials (RCTs) for handling intervention non-adherence.  
Study design 
Bibliographic databases were searched using predefined search terms..  
Results 
A substantive number of identified studies (56%) were excluded as they only used 
naive per-protocol (PP) analysis for handling non-adherence. Our review included 58 articles 
published between 1991 to 2015. A total of 88 methodological applications were made by 
these studies. The two most used methods were Complier Average Causal Effect (CACE) 
(56%) and Instrumental Variable (IV) (23%) predominantly with the use of maximum 
Likelihood (ML) estimators. These alternative applications typically produced treatment 
effects greater than the intention-to-treat (ITT) effect but as their standard errors were larger 
there was no statistical difference between the methods.  
Conclusion 
A substantive proportion of RCTs rely on naive PP for handling non-adherence.  
Recent years have seen an increasing number of applications of more appropriate statistical 
methods, in particular CACE and IV methods. However, these later methods rely on strong 
underlying assumptions that may be vulnerable to violation. More empirical studies are 
needed that directly compare the usability and performance of different statistical methods 
for non-adherence in RCTs.  
Keywords: Non-adherence; Non-compliance; Randomised controlled trial; Methodological 
review; Causal effect modelling; Statistical methods 
Running title: Methodological review of statistical methods for handling non-adherence in 
RCTs. 
(Word count: 192, excluding Title, Headings, Keywords and Running title.)  
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What is already known 
 Randomised controls trials (RCTs) often suffer from non-adherence or non-
compliance of trial participants to the intervention(s) protocol to which they are 
randomised.  
 Per-protocol (PP) and as-Treated (AT) are two naïve analytical methods for 
handling non-adherence in RCTs, which are prone to serious selection bias and 
cannot claim causal treatment effect. 
 Several statistical applications based on causal inference are now available to 
more appropriately adjust treatment effect for non-adherence in RCTs data. 
What this study adds  
 Our methodological review shows that, a large proportion of RCTs continue to rely 
on naïve PP method for handling intervention non-adherence.  
 Maximum likelihood (ML) based Complier Average Causal Effect (CACE) and 
Instrumental Variable (IV) are more appropriate approaches to handling non-
adherence in RCTs. 
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(Word count: 3,054 excluding headings, subheadings, tables/figures, conflict of interest, 
authors’ contribution, references) 
 
1. Introduction 
 
Randomised controlled trials (RCTs) and systematic reviews of RCTs provide the 
highest level of evidence for assessing the effects of healthcare interventions.1 Researchers, 
however, still face challenges when undertaking RCTs. One of these is the non-
adherence/non-compliance of trial participants to the intervention(s) protocol to which they 
are randomised.  
 
Non-adherence has been shown to be associated with poorer patient outcomes, 
including higher mortality.2 A meta-analysis across 569 trials estimated an average 
treatment non-adherence rate of 25%,3 while another study reported the rate  23%.4 Current 
reporting guidelines for RCT (Consolidated Standards of Reporting Trials [CONSORT]) 
recommend the intention-to-treat (ITT) approach i.e. outcomes are compared according to 
original group allocation regardless of whether participants received the intervention 
according to the protocol or not.5, 6 By doing so, ITT evaluates effectiveness of an 
intervention by mirroring the non-adherence to treatment that may occur in real-world 
practice. Whilst this may be true, it is argued that by ignoring non-adherence, ITT 
underestimates the ‘true (or causal) effect’ of the intervention because the analysis is diluted 
by non-compliers.7-9  
 
A commonly used approach by analysts to handling non-adherence is  per protocol 
(PP) analysis  where the outcomes of intervention are compared according to initial random 
allocation but excluding those participants who do not adhere to the intervention protocol.10, 
11
 A systematic review of 100 RCTs identified 47% studies to have adopted some form of PP 
analysis.12 The PP approach is prone to serious selection bias as it fails to preserve the 
original randomisation and causality of treatment effect cannot be claimed.13 ‘As treated’ 
(AT) analysis is another variant of non-ITT analysis,14, 15 that classifies participants according 
to the intervention they receive regardless to their adherence to the trial protocol and like PP 
analysis is subject to selection bias.16, 17  
 
Several statistical methods have been developed for estimating causal treatment 
effects that take account of intervention non-adherence without introducing the biases 
inherent to PP or AT analyses. The statistical framework for causal inference in RCTs was 
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developed by Rubin, referred to as Rubin’s Causal Model (RCM) where each participant is 
assumed to have a set of counterfactual outcomes.18-21 Under the RCM framework, several 
methods developed for handling non-adherence, including Instrumental Variable (IV) 
approach from the field of econometrics,22 Complier Average Causal Effect (CACE) by 
Rubin,14, 23 and Structural mean models (SMM) by Robins.24 To our knowledge there has 
been no comprehensive review of the use of these statistical methods and their pros and 
cons.  
  
We undertook a methodological review of RCTs that described statistical methods for 
handling non-adherence to intervention protocol. Given the bias associated with the 
methodology, we excluded studies that utilised PP analysis alone. The aims were to: (1) 
assess the range of statistical methods reviewed and applied in RCTs to handle non-
adherence; (2) review the relative pros and cons of these statistical methods; (3) Make a 
pooled comparison of the treatment effects estimated by ITT and proposed statistical 
methods for handling non-adherence.    
 
2. Methods 
We conducted and reported this methodological review in accordance with the 
PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) 
statement.25 
 
2.1 Literature search strategy 
We searched a number of bibliographic databases i.e. EMBASE (OvidSP), PsycInfo 
(OvidSP), MEDLINE (OvidSP), CINAHL (EBSCOHOST) and Cochrane Library for 
Methodological Studies (Wiley Online Cochrane Library) from inception to June 2015. 
Database specific Boolean search strategies were developed using key terms i.e. ‘intention 
to treat’, ‘as-treated’, ‘per protocol’, ‘non-adherence’, ‘complier average causal effect’, 
‘CACE’ (and synonyms).  The reference lists of the included papers were manually checked. 
Details of the search strategy are provided in the e-appendix (A).  
 
2.2 Study selection  
We included RCTs that reviewed statistical methods for handling non-adherence and 
applied these methods to actual/simulated trial participant data. Studies were excluded if: (1) 
they were available only as abstracts/titles and not as a full publication; (2) they adjusted for 
non-adherence but provided no information on the statistical basis of this method (this 
included studies that simply stated that they used ‘IV’ or ‘CACE’ analysis but gave no further 
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methodological details);26 (3) they applied statistical methods for handling any potential 
confounding/bias but this was unrelated to non-adherence to intervention protocol.27  
 
2.3 Data extraction 
A database was compiled that captured information on characteristics of included 
studies, i.e. title, authors, journal, year of publication, population disease area, type of 
intervention, randomizing unit, study duration, type of outcomes, sample size and estimated 
treatment effect by ITT method and by the proposed methods. Detailed information was 
extracted on the method of statistical analysis applied i.e.  name of the statistical 
method/framework, statistical estimators/algorithm applied to implement the technique and 
any advantages/disadvantages of these statistical method as stated by authors.  
 
2.4 Data analysis and presentation 
A descriptive approach was taken to data presentation using frequencies, means and 
medians. Pooled comparison of direct treatment effects across studies was not feasible as 
studies had varied outcomes. For comparison of treatment effect between ITT and the 
proposed methods, we compared whether the treatment effect by ITT was larger or smaller 
compared to the effect estimated by the proposed method (coded ‘yes/no’) and presented 
the results in frequency (%). Further, absolute z-statistic [(treatment effect / standard error 
(s.e.)] was calculated for each method application and the pooled mean z-statistic was 
compared between ITT and proposed methods. This pooled comparison accounted for 
within-study variance by subtracting each proposed method z-statistic from ITT-z-statistic 
before calculating pooled mean z-statistic i.e. ∑ [(Zp – ZITT ) / n], where Z is the z-statistic for 
proposed (p) or ITT method and n is the number of applications. The pooled z-statistic was 
also used to compare treatment effect between IV vs CACE method by meta-regression 
accounting for non-adherence rate. Applications made on simulated data and applications 
involving Bayesian method were excluded from these comparisons. Authors presented 
information in various formats i.e. presenting coefficient and 95% confidence interval (CI), 
presenting coefficient and s.e or presenting coefficient and the P-value only. We derived 
required statistic applying appropriate formulae,28-30 where applicable. Where results from 
several models were presented i.e. model comparisons from sensitivity analyses, for data 
extraction, we considered the optimum model suggested by the author. Analyses were 
undertaken using statistical software Stata, version 15.31  
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3. Results 
 
3.1 Selection of included RCTs 
The literature searches resulted in a total of 4,664 titles/abstracts, of which 58 were 
eligible for inclusion (Figure 1). A total of 2,591 (56%) of the abstracts were excluded 
because authors exclusively relied on PP analysis to deal non-adherence. A small number 
of studies were also excluded for applying AT analysis (26 studies, 0.56%) and modified ITT 
(84 studies, 1.8%) as both are forms of PP analysis.12 The other reasons for exclusions were 
applications that were non-RCTs, unrelated to handling non-adherence or lacked 
methodological details.   
 
 
 
Figure 1: Flow of studies through inclusion and exclusion process 
 
Initial sample of abstracts screened (n = 4664)
Excluded (n = 4508)
- Title/abstract unavailable: 143
?- Conference/symposium abstracts: 20
?- Study protocol/design: 39
?- Un-related to handling non-adherence/Not RCTs: 1605
?- Per-protocol (PP) analysis: 2591
?- Modified intention-to-treat analysis (mITT): 84
?- As-treated (AT) analysis: 26 
Manual screening (n = 27)
Full-text assessed for eligibility (n = 183)
?- Methods applied for other purposes: 63
?- Lacks methodological details/Pure application: 23
?- Commentary/review/discussion: 36
?- Methods not applied to any dataset:3 
Excluded (n = 125)
Total articles included (n = 58)
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3.2 Characteristics of included RCTs  
Detailed description of included studies is given in the e-Appendix (B). Summary of 
study characteristics is presented in Table-1. Majority of included studies were published in 
statistical/methodological journals. Studies were undertaken across a wide range of patient 
and intervention types, study sizes, duration and were applied across a range of outcome 
types (continuous/binary/count/time-to-event).  
Characteristics Number Percent (%) 
Number of articles 58 100 
Year of publication (n = 58) – – 
1991-1999 12 21 
2000 - 2007 21 36 
2008 - 2015 25 43 
Journals (n = 58) – – 
Statistics in medicine 20 34 
Biometrics 8 14 
Biostatistics 5 9 
Journal of the American Statistical Association 4 7 
Controlled Clinical Trials 2 3 
Journal of the Royal Statistical Society 2 3 
Psychological Methods 2 3 
American journal of epidemiology 1 2 
Biometrical Journal 1 2 
Biometrika 1 2 
British Journal of Psychiatry 1 2 
Clinical trials 1 2 
Family process 1 2 
Health Services & Outcomes Research Methodology 1 2 
Journal of Biopharmaceutical Statistics 1 2 
Journal of Clinical Epidemiology 1 2 
Journal of Educational and Behavioral Statistics 1 2 
Psychological Medicine 1 2 
Statistica Sinica 1 2 
Statistical Methods in Medical Research 1 2 
The American journal of drug and alcohol abuse 1 2 
The annals of statistics 1 2 
Study population clinical area (n = 58) – – 
Mental health 17 29 
Cardiology 7 12 
Infectious disease 5 9 
Oncology 4 7 
Others 20 34 
Simulation study/NA 5 9 
Follow up duration (n = 58) – – 
1 year 11 19 
1-2 year 19 33 
>2 years 15 26 
Not reported 13 22 
Type of intervention (n = 58) – – 
Drug 21 36 
Psycho-therapy 8 14 
Behavioural 8 14 
Other 16 28 
Simulation study (N/A) 5 9 
Type of outcome (n = 58) – – 
Binary 29 50 
Continuous 19 33 
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Count/Time-to-event 10 17 
Sample size (n = 58) – – 
<400 19 33 
400-1000 14 24 
>1000 18 31 
Not-reported/NA 7 12 
Randomising unit (n = 58) – – 
Individual 46 79 
Cluster 5 9 
Meta-analysis 1 2 
Simulation study (N/A) 6 10 
% Non-adherence: Median (range) – 34% (2% to 78%) 
 
 
Table 1: Summary of included study characteristics 
 
A significant rise was observed in the published literature in this area of 
methodological research since 1999. Per-year average rate of publication (IRR: incidence 
rate ratio) was higher at the later periods compared to the 1991-1999 period (IRR for 2000-
2007: 1.56, 95% CI: 1.00 to 2.45, p<0.05; IRR for 2008-2015: 1.72, 95% CI: 1.11 to 2.65, 
p<0.01).  
 
  
3.3 Statistical methods and estimators used in included RCTs to handle non-
adherence 
A total of nine methods for handling treatment non-adherence were described across 
the included studies (Table 2a). Some of these studies applied more than one method using 
different estimators resulting in a total of 88 statistical method applications. Studies that were 
judged to be variants of a common statistical approach were grouped under broader 
approach i.e. ‘Longitudinal Complier Average Causal Effect’ or ‘Complier Average Causal 
Effect within Effect Class (ECACE)’ were grouped under ‘Complier Average Causal Method 
(CACE)’ as they broadly have similar statistical framework.  The two most common 
statistical methods applied were the Complier Average Causal Effect (CACE) (49/88 
applications, 56%) and Instrumental Variable (IV) (20/88 applications, 23%). Authors applied 
the term ‘IV’ for both ‘method’ and ‘estimator’ where ‘IV-method’ refers to the causal 
instrumental variable framework23 and ‘IV-estimator’ refers to implementation of a particular 
method applying two-stage least square (2SLS) estimator.32 A total of 10 estimators (Table 
2b) were identified, the most common being Maximum Likelihood (ML) estimator in 33% (n = 
29), Method of Moment (MOM) base estimator in 22% (n = 19), Instrumental Variable (IV) 
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estimator in 19% (n = 17) and Bayesian estimators were used in 10% (n = 9) of the 
applications.  
 
Sl 
# a) Methods Method elaboration 
Number 
(%) b) Estimators Estimator elaboration 
Number 
(%) 
1 CACE Complier average causal effect model 49 (56) ML Maximum likelihood 29 (33) 
2 IV Instrumental variable model 20 (23) MOM Method of moments 19 (22) 
3 SNMM Structural nested mean model 7 (8) IV Instrumental variable estimator 17 (19) 
4 ATR Adjusted treatment received model 4 (5) BI Bayesian inference 9 (10) 
5 RPSFTM Rank preserving structural failure time model 3 (3) G-estimator G-estimator 5 (6) 
6 C-PROPHET Rank preserving structural failure time model 2 (2) Cox-PH Cox-proportional hazard estimator 4 (5) 
7 CALM Compliers proportional hazards effect of 
treatment with proportional Hazards model 
1 (1) WLS Weighted least square 2 (2) 
8 Cox-Reg1 Causal accelerated life model 1 (1) GSMM Generalized structural mean 
model estimator 
1 (1) 
9 Cox-Reg2 Regression adjustment with Cox-model 1 (1) ISM Intensity score method 1 (1) 
 
 
  
WGSNM Weighted generalized structural 
mean model 
1 (1) 
  
Total 
  
88 (100) 
    
88 (100) 
 
Table 2: Statistical methods (a) and their estimators (b) as stated by the authors, 
applied for handling non-adherence 
 
Figure 2/a shows the different estimators used for applications of CACE methods. 
ML base estimators were implemented with Expectation Maximization (EM) algorithm,33 and 
Bayesian Inference (BI) base methods were implemented both with EM and Markov-Chain 
Monte-Carlo (MCMC) algorithm.34 As shown in Figure 2/a, 49% (n = 24) of the CACE 
applications were made using ML estimators. Figure 2/b shows all other statistical methods 
and the frequencies of the use of their different estimators.  
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Figure 2: a) Use of varied estimators for estimating CACE and (b) other methods 
 
3.4  Pros and cons of statistical methods presented by authors  
The remainder of the methods section and Table 3 provide an overview of the 
statistical basis of the statistical methods and stated pros and cons of these approaches. 
 
3.4.1 Complier Average Causal Effect (CACE) 
Based on counterfactual outcome,21 the CACE method was introduced by Angrist et 
al. for estimating causal effects in the presence of non-adherence.23 In CACE analysis the 
potential adherence classes are stratified into four principal strata based on principal 
stratification,35 i.e. i) ‘Compliers’ i.e. receive treatment when they are assigned to it, ii) 
‘Never-takers’ i.e. do not receive treatment when they are assigned to it, iii) ‘Always-Takers’ 
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i.e.  always receive the treatment regardless of randomisation and iv) ‘Defiers’ i.e.  always 
do the opposite of what is assigned and assumed to be non-existent. In addition to 
randomisation and the stable unit treatment value assumption (SUTVA),36, 37 there are two 
key assumptions that need to be fulfilled for CACE model to be identified: (1) the effect of 
treatment assignment on outcomes entirely operates through treatment receipt status of 
participants, known as “exclusion restriction” (ER). ER in other words states that under true 
randomization, the proportion of non-compliers in the control group (had they been offered 
the treatment) and their outcomes are similar to the proportion of observed non-compliers 
and their outcomes in the treatment group; (2) The “monotonicity” assumption implies that 
there are no ‘defiers’ meaning no participants will refuse treatment when assigned to 
treatment and will seek treatment when assigned to control. Though the initial CACE 
estimator proposed by Angrist et al. was an IV estimator,23 we identified several other 
estimators for CACE applied into different settings (Figure 2a). Our findings, across several 
types of CACE applications, suggest that ML-base estimation was applied more often than 
other estimators and the reason may be that ML estimates are considered more efficient 
than 2SLS (Two-Stage Least Square) based IV estimators.38-40 We also found applications 
of IV estimators in combination with ML estimators in estimating CACE and this combination 
contributed to substantial methodological development.41 Missing data adds another level of 
complexity in presence of treatment non-adherence and in over half of CACE applications 
(24/47) authors provided guidelines for handling missing data. CACE also has been 
implemented in cluster randomised trials where intra-class correlation (ICC) from similar 
adherence behaviour at cluster level may compromise estimated treatment effects.42-45 
When there are multiple arms involved, CACE model may suffer from non-identifiability 
issues or may require complex modelling assumptions,46, 47 and Bayesian methods may be 
applied addressing such complexities.48 The fundamental limitation of the CACE approach is 
that the underlying assumptions i.e. ER, monotonicity are not easily testable,49-52 and if 
violated CACE estimates may be biased.41, 52, 53  
 
3.4.2 Instrumental variable (IV) 
An IV is an exogenous variable that influences the outcome solely through a binary 
post-treatment variable that identifies whether participants adhered to treatment or not.21, 22 
Typically in RCTs, an IV is the randomizing variable and participants’ adherence status is 
the endogenous variable through which outcome is affected. The assumption that outcome 
solely depends on adherence status is equivalent to the ER assumption discussed in the 
CACE section above. Therefore, in a two-arm trial design where participants’ choice to post-
randomisation switching between arms is restricted, an IV estimates alternate CACE 
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estimates given same estimator applied.49 Typically IV estimators are implemented with 
2SLS32 estimators, however, ML-based IV estimators are also used.54 In our selected 
studies, we separately identified ML-base IV estimators where authors were explicit about it. 
We found IV methods, like CACE, being applied in varied scenarios. However, IV with 2SLS 
is likely to estimate treatment effect on complete case basis and valid only when missing 
data are ignorable.32 When compliance rate is low, 2SLS-base IV estimator produces large 
effects compared to ITT and produces large variances which makes it a less attractive 
estimator.55 In such scenarios, ML is a more efficient estimator of IV.56 A variation of IV 
method is Adjusted Treatment Received (ATR) method introduced by Nagelkerke57 with an 
adjustment made to error terms. The distinction to typical IV method is that in ATR, the error 
terms from first stage endogenous regression is added to the model as a covariate to allow 
adjustment for any unmeasured confounding.  
 
 
3.4.3 Other statistical methods 
Structural Mean Model (SMM)/Structural Nested Mean Model (SNMM) was 
introduced by Robins.24 The framework provides causal treatment effect for observed 
adherence comparing with a conditional reference level of adherence.47 Linear additive 
framework is used for continuous outcomes and multiplicative framework is used for binary 
outcomes. Models are estimated with the G-estimator (GE) proposed by Robins and 
Tsiatis.58, 59 The appealing aspect of SMM is that causal parameters can be estimated for 
varying levels of adherence. However identifying reference level of compliance may be 
challenging.60 Another version of SMM applied to accelerated failure time (AFT) model (time 
to event survival data with time as outcome) is Rank Preservative Structural Failure Time 
model (RPSFTM).61, 62 They are called rank preserving because they use a class of rank 
estimators for subjects’ failure.62 In practice, G-estimators have not been widely adopted due 
to level of complexities involved in implementation.63 For handling non-adherence in 
continuous time survival data include Cox-reg(1,2), Complier proportional hazard effect of 
treatment (C-PROPHET) model and Causal accelerated life model (CALM).64, 65 Cox-reg(1,2) 
both are adherence adjustment base Cox-regression implemented by Cox-PH estimator. 
Cox-reg1 is implemented in situations when compliance is ‘all-or-nothing’ i.e. either patients 
receive the treatment, or they do not and Cox-reg2 is implemented when compliance is 
partial. CALM and C-PROPHET both have CACE like framework where CALM is applied to 
AFT model and C-PROPHET is applied to continuous time survival data.  
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Methods* Fre
que
ncy 
Estimators* 
 
Method description Strengths Limitations in implementation 
CACE 49 BI/IV/ML/MO
M 
Based on principal stratification 
and counterfactual outcome 
rather observed outcome, 
CACE estimate relates to 
treatment effect for participants 
who would have complied with 
the treatment had they been 
offered it. 
i) In presence of non-adherence, 
unlike PP/AT, it yields causal 
effect of treatment on the treated 
ii) Randomization based 
estimate of efficacy iii) By using 
pre-treatment covariates 
identifiable CACE model is 
feasible instead forcing 
exclusion restriction assumption. 
iv) Cell specific i.e. 'always-
takers', 'never-takers' treatment 
effect estimation is possible. 
i) Assumptions are not directly 
testable and may not reflect the 
real world scenario under non-
adherence ii) CACE estimates 
can be biased if assumption is 
violated and the bias can be 
substantial with low compliance 
rate iii) The strong assumptions 
limits the flexibility of CACE 
modelling in practice iv) 
Encounters difficulty when 
number of randomized arms and 
adherence categories increase. 
IV 20 BI/G-
estimator/IV/
ML/MOM 
Instrumental variable method 
historically grounded in 
econometric theory where an 
instrument is an exogenous 
variable that influences the 
outcome through adherence 
related post-treatment variable 
only. 
i) IV estimate does not require 
an assumption of homogeneous 
treatment effects, under 
exclusion restriction and the 
monotonicity assumptions ii) 
Method is not sensitive to 
differences in baseline risk 
between compliers and non- 
compliers iii) IV tends to have 
superior RMSE unless the 
compliance rate is low or zero. 
i) Outcome may be affected by 
other means rather solely 
through treatment received and 
randomization. ii) Method is 
most sensitive to violations of 
exclusion restriction and to the 
monotonicity assumption when 
there are few compliers. iii) With 
2SLS estimator and low 
compliance rate, IV can produce 
large variances iv) 
Implementation with 2SLS can 
only be feasible if missing data 
are ignorable. 
SNMM 7 GE/WGSNM/I
SM/IV/MOM/
WGSNM/WL
S 
Method relates to comparing 
mean of the outcome at an 
observed compliance level with 
the mean of the potential 
outcome at some reference 
level. 
i) Provide randomization based 
causal effects at varying level of 
adherence ii) Cause–effect 
relationships are established by 
considering a potential 
treatment-free outcome for each 
observational unit.  
i) With binary outcomes, in some 
instances with complex study 
design i.e. three arms, the 
estimating equation has no 
solution. ii) G-estimation can be 
complex in implementation. 
ATR 4 IV Variation of IV method with error 
term from endogenous 
regression added in the model 
as covariate 
i) Method copes with missing 
data problems as the first stage 
uses all randomized participants. 
Only the second stage is 
affected with missing data 
i) Method only valid when 
patients switch between 
treatment arms, for example 
when one arm consists of 
placebo therapy and a placebo 
effect is not anticipated. 
RPSFTM 3 GE Estimates parameters of a class 
of semi-parametric failure time 
models, using a class of rank 
estimators. These models are 
the structural version of the 
"accelerated failure time model 
with time-dependent covariates" 
i) Yields valid results for both 
outcome-dependent and 
outcome-independent treatment 
non-compliance ii) designed to 
consistently estimate causal 
effects on the treated, without 
direct assumptions about the 
compliance selection 
mechanism 
i) RPSFTM makes a strong non-
interaction assumption which in 
certain settings might be 
considered biologically 
implausible ii) G-estimation can 
be complex in implementation. 
C-PROPHET 2 Cox-PH Randomization based 
proportional hazard model for 
continuous survival data 
i) Model framework is similar to 
CACE and provides estimates 
equivalent to CACE 
i) Allows only binary/all or none 
compliance ii) I Under time-
varying noncompliance the 
model maybe biased 
Cox-Reg1-2 2 Cox-PH Cox-Proportional Hazard model 
for continuous survival data 
adjusting for non-adherence 
i) Yield valid causal estimates 
under random non-adherence 
i) Under non-random adherence, 
estimates can be biased 
CALM 1 ML Accelerated Failure to Time 
(AFT) model for survival data 
that relates each observed 
event time in the treated group 
to a potential event time that 
would have been observed if the 
control treatment had been 
given throughout the trial 
i) Allows cross-over type non-
adherence between arms ii) 
Estimates hazard ration 
equivalent to CACE ii) Does not 
rely on homogenous population 
i)  The model may produce 
extreme values and larger error 
terms 
*Please refer to Table 2 for the elaboration of the method/estimator acronyms  
 
Table 3: Summary of methods, pros and cons as stated by the authors 
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3.5 Comparison of estimated treatment effects 
We were able to compare treatment effect for 68/88 applications. The majority of the 
alternative methods (n = 48, 71%) produced treatment effects that were greater than the 
treatment effect estimated by ITT. For 11 applications (16%) estimates were similar for both 
ITT and the proposed methods. For all alternative methods, excluding the Bayesian 
applications, 95% CIs overlapped with the CIs of ITT either at lower or upper bound region.   
 
64/88 applications contributed to the calculation of standard errors and z-statistics. In 
83% of the applications (53/64), standard errors for the alternative methods were larger than 
the s.e. of ITT estimates.  After accounting for within study variation, average z-statistic from 
proposed methods were greater by +0.13 SD (95% CI: -0.99 to 1.71). We found 7 out of 58 
studies (12%) achieved significant treatment effect by applying an alternative method which 
was not achieved by the ITT method. 
 
In meta-regression, when accounted for percent non-adherence rate, z-statistic for IV 
method was no different than z-statistic from ITT (-0.01, 95% CI: -0.27 ti 0.26) but z-statistic 
from CACE were greater by +0.18 SD (0.18, 95% CI: -0.01 to 0.35). CACE estimates were 
higher by the same amount when compared to IV.  
  
 
 
4. Discussion 
In this review, across 58 studies, a wide variety of statistical methods against ITT 
were identified for handling treatment non-adherence. The median intervention non-
adherence was 38% ranging across studies from 2% to 78%. The two most commonly used 
methods were Complier Average Causal Effect (CACE) and Instrumental Variable (IV). 
Overall, there was no significant difference between the pooled z-statistics from ITT and the 
alternative methods. In general, the majority of the proposed applications (83%) produced 
larger error variance compared to the error variance produced by ITT. We note that use of 
the CACE method resulted in larger z-statistics compared to the IV method when accounting 
for non-adherence rate.  
 
We are aware of two previous systematic reviews undertaken to assess the 
analytical approaches to the handling of treatment protocol non-adherence in RCTs. Dodd et 
al.12 summarised the extent to which non-adherence to treatment protocol is reported in 
RCTs. However, this study did not identify methods apart from the conventional ITT, PP and 
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AT analysis approaches. Adewuyi et al.66 studied non-adherence in surgical intervention and 
reported that 63% of the studies adopted ITT, 21% PP and 3% AT analysis. Our systematic 
review is therefore the first to identify and systematically reviewed statistical methods that 
have been developed to handle non-adherence using a causal inference framework.  
 
The CACE and IV methods are flexible and have been applied across a range of 
RCT designs. One of the benefits of the CACE application is that cell-specific treatment 
effect can be obtained which can provide valuable insights for researchers in relation to 
various types of adherence, whereas this opportunity is limited for the IV approach. We also 
found good number of applications of MOM estimators (19/88, 22% applications), but we 
avoided emphasizing on it as it relies on simple cell means and ignores distributional error 
terms which can be erroneous.52, 67 According to our findings, both CACE and IV methods 
are applicable to varieties of scenarios and both rely on strong assumptions that are 
vulnerable to violations. Unless there are direct ways of testing the assumptions, it is not 
readily verifiable whether the applied methods captured the true treatment effect or simply 
inflated the treatment effect influenced by level of adherence. 
 
5. Strengths and limitations  
The strength of this study was its use of a systematic review approach to identify 
studies for inclusion. However, it has a number of limitations. Study selection and data 
extraction was undertaken by a single reviewer (MM) although the opinion of a second 
reviewer (RST) was available. We were unable to compare treatment effects estimated by 
different statistical methods because of their varied outcomes. The comparison of pooled z-
statistic may not be an ideal approach, but this provides an indication of location of treatment 
effect estimated by different methods around the region of significance. We excluded studies 
that implemented relevant methods purely for application purposes instead of providing 
methodological guidance for handling sub-optimal adherence and also studies that used 
statistical methods for handling general confounding other than handling non-adherence 
exclusively e.g. propensity score (PS), inverse probability weighting (IPW). These methods 
have wider applications in observational studies for adjusting general confounding based on 
probabilistic weighting, but they directly do not contribute to the formation of causal 
frameworks for handling non-adherence.  
 
6. Implications for practice and policy 
Usually the ITT estimate of a treatment effect will be smaller than the ‘true’ effect 
since if the treatment works, non-compliance to treatment means suboptimal effects. 
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Therefore, the search for an alternative to ITT is a growing area of interest. Perhaps 
surprisingly, we found that a large number of RCTs continue to use PP methods despite the 
major limitations of this approach. CACE and IV methods are two important unbiased 
alternatives to ITT when adherence to treatment is sub-optimal and this review shows that 
these methods have been applied to a wide range of RCTs. However, given both suffer from 
strong underlying assumptions these methods are always reported in addition to ITT 
analysis and regarded as a sensitivity analysis.  
 
7. Conclusions 
Our review found that the alternative methods for handling non-adherence rely on 
strong assumptions that may be vulnerable to violations. More empirical studies are needed 
that directly compare the usability and performance of different statistical methods for non-
adherence in RCTs.  
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Highlights: 
 
 
 What is already known 
 Randomised controls trials (RCTs) often suffer from non-adherence or non-
compliance of trial participants to the intervention(s) protocol to which they are 
randomised.  
 Per-protocol (PP) and as-Treated (AT) are two naïve analytical methods for 
handling non-adherence in RCTs, which are prone to serious selection bias and 
cannot claim causal treatment effect. 
 Several statistical applications based on causal inference are now available to 
more appropriately adjust treatment effect for non-adherence in RCTs data. 
What this study adds  
 Our methodological review shows that, a large proportion of RCTs continue to rely 
on naïve PP method for handling intervention non-adherence.  
 Maximum likelihood (ML) based Complier Average Causal Effect (CACE) and 
Instrumental Variable (IV) methods are applied in various settings to handle non-
adherence in RCTs. 
 
